Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anticancer effect of magnetic fluid hyperthermia using poly(acrylic acid)-coated magnetic nanoparticles as evident by apoptosis of lung cancer cells A549.

Journal of thermal biology·2026

Same author

Low-Proliferative Invasive Mucinous Carcinoma of the Breast in an Octogenarian: A Case Report Highlighting Pathology-Guided De-escalation.

Cureus·2026

Same author

Severe Familial Chylomicronemia Syndrome With Refractory Hypertriglyceridemia and Multisystem Complications Managed With Chronic Plasmapheresis and Olezarsen: A Case Report.

Cureus·2026

Same author

Engagement of Parents in an Evidence-Based Teen Pregnancy Prevention Program for Native American Adolescents.

Family & community health·2026

Same author

Magnetic Fluid Hyperthermia-Induced Apoptosis: Evaluating the Effect of Ho-Doped Mn-Zn Magnetic Nanoparticles on Cervical, Breast, and Bone Cancer Cells in Vitro.

ACS omega·2026

Same author

Effect of Mn-Doped ZnFe<sub>2</sub>O<sub>4</sub> Ferrites on Structural Changes and Magneto-Optical Behavior in Nematic Liquid Crystals.

Materials (Basel, Switzerland)·2025

Search research articles

Related Experiment Video

Updated: Aug 16, 2025

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

HER3 Alterations in Cancer and Potential Clinical Implications.

Mary Kate Kilroy¹, SoYoung Park^1,2, Wasim Feroz¹

¹Department of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.

|December 23, 2022

Summary

This summary is machine-generated.

The human epidermal growth factor receptor 3 (HER3) is implicated in various cancers. Understanding HER3 mutations and activation is key for developing targeted therapies and overcoming treatment resistance.

Keywords:

HER3 alteration bladder cancer breast cancer colorectal cancer lung cancer

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Related Experiment Videos

Last Updated: Aug 16, 2025

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

The human epidermal growth factor receptor 3 (HER3) is increasingly recognized for its role in cancer progression.
HER3 activation and mutations are observed across multiple cancer types, including bladder, breast, colorectal, and lung cancers.
Tumor genetic sequencing frequently identifies HER3 alterations, highlighting its clinical relevance.

Purpose of the Study:

To review the role of HER3 activation and mutations in the progression of bladder, breast, colorectal, and lung cancers.
To examine HER3 alterations as potential mechanisms of resistance to targeted therapies.
To discuss the implications of HER3 targeting drugs currently in development.

Main Methods:

Literature review focusing on studies investigating HER3 in cancer progression and targeted therapy resistance.
Analysis of reported frequencies of HER3 mutations across different cancer types.
Overview of current and emerging HER3-targeting therapeutic strategies.

Main Results:

HER3 mutations occur in up to approximately 10% of tumors, varying by cancer type.
HER3 activation is linked to tumor growth and progression in key solid tumors.
HER3 alterations represent a significant factor in the development of resistance to cancer therapies.

Conclusions:

HER3 is a critical factor in the pathogenesis and progression of several major cancers.
Targeting HER3 holds promise for overcoming therapeutic resistance and improving patient outcomes.
Ongoing development of HER3-targeted drugs may offer new treatment avenues for patients with specific tumor alterations.